Anzeige
Mehr »
Login
Montag, 14.10.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Größtes Gold-Investment 2024? NexGold Mining - Fusion könnte der Katalysator sein, den Anleger brauchen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 905948 | ISIN: VGG4481U1066 | Ticker-Symbol: HGY
Berlin
14.10.24
08:08 Uhr
1,740 Euro
+0,070
+4,19 %
Branche
Sonstige Technologie
Aktienmarkt
ASIEN
1-Jahres-Chart
HIGHWAY HOLDINGS LIMITED Chart 1 Jahr
5-Tage-Chart
HIGHWAY HOLDINGS LIMITED 5-Tage-Chart
PR Newswire
29 Leser
Artikel bewerten:
(0)

Highway Holdings Limited: Highway Holdings Reports Second Quarter Fiscal Year 2025 Results

  • 60.1% Year Over Year Increase in Second Quarter Revenue
  • 117.8% Year Over Year Increase in Second Quarter Gross Profit
  • Cash and Cash Equivalents of $1.28 Per Diluted Share

HONG KONG, Oct. 10, 2024 /PRNewswire/ -- Highway Holdings Limited (Nasdaq: HIHO, "the Company" or "Highway Holdings") today reported results for the second quarter of fiscal year 2025 and the six months ended September 30, 2024, with second quarter of fiscal year 2025 revenue growth of 60.1% and gross profit growth of 117.8% on a year over year basis.

Roland Kohl, chairman, president and chief executive officer of Highway Holdings, noted, "While the positive results reflect an improving environment at our customers, we still have a lot of ground to make up to return to our normalized pre-COVID business level. The rebound continues but has been slowed by the uncertain macro environment, following the fallout of COVID, as orders for customer products have been adversely impacted by the Russia / Ukraine war and the conflict in Mid-East. In addition, our business progress is not immediately reflected on a net income comparison, and we caution investors this is not an accurate measure, because we benefitted in the year ago period from the reversal of previously taken bad debt provisions. With that being said, we are encouraged with our progress and expect an improving business environment over the coming quarters will help our business now that we have stopped the bleeding and can focus on expanding revenue growth, profitability and free cash flow."

Mr. Kohl concluded, "We are cautiously optimistic that we have come through the worst part of this low business cycle. Even with our existing products still experiencing below normal levels of demand, we are coming online shortly with the new motor project we previously announced. Production is expected to start in the fiscal third quarter of 2025 and should ramp up in the fiscal fourth quarter of 2025. As a result, if our core existing business remains stable or improves slightly, the positive impact of the additional new business will help drive a further improvement in results. Our company is financially very healthy with over $5.6 million in cash on hand and a net cash positive position. At the same time, as part of our business growth strategy, we are evaluating numerous possible ventures, which could substantially improve the Company's future. We are fully committed to building value for the Company and all shareholders, as we continue to build on our track record of success over the long-term."

Select Additional Financial Results:

Gross profit for the second quarter of fiscal year 2025 was $834,000 compared with $383,000 in the year ago period mainly due to the 60.1% increase in sales over the same period. Gross profit as a percentage of sales for the second quarter of fiscal year 2025 was 39.4 percent, compared to 29.0 percent in the year ago period. Gross profit for the first half of fiscal year 2025 was $1,495,000 compared with $760,000 in the year ago period. Gross profit as a percentage of sales for the first half of fiscal year 2025 was 37.4 percent compared with 28.5 percent in the year ago period.

Selling, general and administrative expenses for the second quarter of fiscal year 2025 increased to $724,000 from $272,000, primarily reflecting the above-noted bad debt provision reversal in the year ago period.

Net income for the second quarter of fiscal year 2025 reflects a currency exchange gain of $58,000 compared to a $14,000 gain in the year ago period mainly due to a weakening of the Kyat. The Company reported a currency exchange gain of $96,000 for the first half of fiscal year 2025, compared with a $31,000 gain in the year ago period.

The Company had interest income of approximately $58,000 for the second quarter of fiscal year 2025, and interest income of approximately $103,000 for the first half of fiscal year 2025 due to the increase in interest rates.

The Company's balance sheet remains strong, with total assets of $11.0 million dollar and cash and cash equivalents in excess of $5.6 million, or approximately $1.28 per diluted share. The cash and cash equivalent amount exceeded all of its short- and long-term liabilities by approximately $1.4 million. Total shareholders' equity at September 30, 2024, was $6.8 million, or $1.54 per diluted share.

About Highway Holdings Limited

Highway Holdings is an international manufacturer of a wide variety of quality parts and products for blue chip equipment manufacturers based primarily in Germany. Highway Holdings' administrative offices are located in Hong Kong and its manufacturing facilities are located in Yangon, Myanmar, and Shenzhen, China. For more information visit website www.highwayholdings.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements which involve risks and uncertainties, including but not limited to economic, competitive, governmental, political and technological factors affecting the company's revenues, operations, markets, products and prices, and other factors discussed in the company's various filings with the Securities and Exchange Commission, including without limitation, the company's annual reports on Form 20-F.

(Financial Tables Follow)

HIGHWAY HOLDINGS LIMITED AND SUBSIDIARIES

Consolidated Statement of Income

(Dollars in thousands, except per share data)

(Unaudited)



Three Months Ended


Six Months Ended



September 30,


September 30,












2024


2023


2024


2023













Net sales

$2,117


$1,322


$3,996


$2,669



Cost of sales

1,283


939


2,501


1,909



Gross profit

834


383


1,495


760













Selling, general and administrative expenses

724


272


1,382


1,049



Operating income/(loss)

110


111


113


(289)













Non-operating items




















Exchange gain /(loss), net

58


14


96


31



Interest income

58


53


103


93


Gain/(Loss) on disposal of assets

-


13


-


13



Other income/(expenses)

5


6


12


6



Total non-operating income/ (expenses)

121


86


211


143























Net income before income tax and non-controlling interests

231


197


324


(146)



Income taxes

0


3


0


6



Net income before non-controlling interests

231


200


324


(140)



Less: net gain attributable to non-controlling interests

0


(13)


(5)


(15)



Net income/(loss) attributable to Highway

Holdings Limited's shareholders

231


213


329


(125)













Net Gain/ (loss) per share - Basic

$0.05


$0.05


$0.08


$(0.03)



Net Gain/ (loss) per share - Diluted

$0.05


$0.05


$0.08


$(0.03)













Weighted average number of shares outstanding










Basic

4,402


4,219


4,379


4,345



Diluted

4,402


4,235


4,379


4,345
























HIGHWAY HOLDINGS LIMITED AND SUBSIDIARIES

Consolidated Balance Sheet

(Dollars in thousands, except per share data)



(unaudited)

Sept 30,


(audited)

Mar 31,


2024


2024





Current assets:




Cash and cash equivalents

$5,614


$6,601

Accounts receivable, net of doubtful accounts

1,982


1,253

Inventories

1,785


1,566

Prepaid expenses and other current assets

156


226

Total current assets

9,537


9,646





Property, plant and equipment, (net)

64


-

Operating lease right-of-use assets

1,142


1,375

Long-term deposits

206


202

Long-term loan receivable

95


95

Investments in equity method investees

-


-

Total assets

$11,044


$11,318





Current liabilities:




Accounts payable

$1,021


$935

Operating lease liabilities, current

621


588

Other liabilities and accrued expenses

1,559


1,789

Income tax payable

484


480

Dividend payable

45


45

Total current liabilities

3,730


3,837





Long term liabilities :




Operating lease liabilities, non-current

507


803

Long terms accrued expenses

40


40

Total liabilities

4,277


4,680





Shareholders' equity:




Preferred shares, $0.01 par value

-


-

Common shares, $0.01 par value

44


44

Additional paid-in capital

12,159


12,117

Accumulated deficit

(4,908)


(5,015)

Accumulated other comprehensive income/(loss)

(516)


(501)

Non-controlling interest

(12)


(7)

Total shareholders' equity

6,767


6,638





Total liabilities and shareholders' equity

$11,044


$11,318













SOURCE Highway Holdings Limited

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.